Literature DB >> 23986551

Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.

Ji Yun Yun1, Young A Kim, Ji-Young Choe, Hyesook Min, Kyu Sang Lee, Youngho Jung, Sohee Oh, Ji Eun Kim.   

Abstract

BACKGROUND: Thyroid cancer is one of the most commonly detected cancers worldwide, and papillary thyroidal carcinoma (PTC) accounts for the majority of thyroid cancers. In contrast to the indolent nature of PTC, anaplastic thyroid carcinoma (ATC) shows an extremely poor prognosis and has not responded to any therapeutic modalities. Many researchers postulate that the dedifferentiation of thyroid follicular cells into primitive cells might be related to the pathogenesis of ATC because several cases of ATC have revealed pre-existing PTC lesions. Additionally, the cancer stem cell (CSC) theory has been widely accepted in the pathogenesis of ATC.
OBJECTIVE: To explore the expression of various CSC markers in thyroid carcinoma tissues and analyse their clinical significance.
METHODS: 133 patients with PTC and 25 patients with ATC were enrolled. Immunohistochemistry for aldehyde dehydrogenase 1 (ALDH1), CD133, CXCR4, ATP-binding cassette (ABC)G2, multidrug resistance associated protein-1 (MRP1), lung resistance protein-1 (LRP), P-glycoprotein 1 (P-Gp1), SOX2, SOX9 and Oct4 was performed using tissue microarray.
RESULTS: CSC marker expression was significantly high in ATC, particularly chemoresistance markers such as ABCG2, MRP1, LRP and CXCR4. In PTC, ABCG2 was highly positive in more advanced pathological stages and was associated with lymph node involvement, with borderline significance. In ATC, high expression of CXCR4 correlated with distant metastasis, and LRP showed a tendency to correlate with lymph node metastasis. High expression of CSC markers was related to shorter overall survival in patients with ATC.
CONCLUSIONS: These results provide strong evidence that CSCs are related to the pathogenesis of ATC and can explain the frequent treatment failure and aggressiveness of ATC.

Entities:  

Keywords:  Carcinoma; Immunohistochemistry; Thyroid Cancer

Mesh:

Year:  2013        PMID: 23986551     DOI: 10.1136/jclinpath-2013-201711

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.

Authors:  Zorica Milošević; Jasna Banković; Jelena Dinić; Chrisiida Tsimplouli; Evangelia Sereti; Miodrag Dragoj; Verica Paunović; Zorka Milovanović; Marija Stepanović; Nikola Tanić; Kostantinos Dimas; Milica Pešić
Journal:  Cell Oncol (Dordr)       Date:  2018-05-22       Impact factor: 6.730

2.  Development and characterization of six new human papillary thyroid carcinoma cell lines.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Junsun Ryu; Yunyun Chen; Michelle D Williams; Adel K El-Naggar; Mihai Gagea; Rebecca E Schweppe; Bryan R Haugen; Stephen Y Lai; Gary L Clayman
Journal:  J Clin Endocrinol Metab       Date:  2014-11-26       Impact factor: 5.958

3.  Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.

Authors:  Zhilan Li; Xiudi Jiang; Peihong Chen; Xuebing Wu; Aihua Duan; Yiyu Qin
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

Review 4.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

5.  Anaplastic Thyroid Carcinoma: A ceRNA Analysis Pointed to a Crosstalk between SOX2, TP53, and microRNA Biogenesis.

Authors:  Walter Arancio; Valeria Carina; Giuseppe Pizzolanti; Laura Tomasello; Maria Pitrone; Concetta Baiamonte; Marco Calogero Amato; Carla Giordano
Journal:  Int J Endocrinol       Date:  2015-01-29       Impact factor: 3.257

6.  Thyrospheres from B-CPAP Cell Line with BRAF and TERT Promoter Mutations have Different Functional and Molecular Features than Parental Cells.

Authors:  Paola Caria; Rita Pillai; Tinuccia Dettori; Daniela Virginia Frau; Patrizia Zavattari; Gabriele Riva; Gabriele Romano; Fabiana Pani; Angela Bentivegna; Roberto Giovannoni; Fabio Pagni; Valeria Sogos; Roberta Vanni
Journal:  J Cancer       Date:  2017-06-03       Impact factor: 4.207

Review 7.  The Role of Snail-1 in Thyroid Cancer-What We Know So Far.

Authors:  Katarzyna Wieczorek-Szukala; Andrzej Lewinski
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

8.  Study on the Antitumor Effect and Glycolysis of Andrographolide in Anaplastic Thyroid Carcinoma.

Authors:  Ke Yang; Ke Wu; Jianguo Feng; Ling Yutian; Xin Zhu; Dong Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-14       Impact factor: 2.629

Review 9.  Thyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review).

Authors:  Yong-Ju Gao; Bo Li; Xin-Yu Wu; Jing Cui; Jian-Kui Han
Journal:  Oncol Rep       Date:  2014-01-14       Impact factor: 3.906

Review 10.  Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.

Authors:  Sabine Hombach-Klonisch; Suchitra Natarajan; Thatchawan Thanasupawat; Manoj Medapati; Alok Pathak; Saeid Ghavami; Thomas Klonisch
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.